BRISTOL-MYERS SQUIBB COMPANY |
Market Closed -
Other stock markets
|
After market 08:00:00 pm | |||
| 44.11 USD | -0.99% |
|
44.59 | +1.09% |
| May. 16 | Everlasting momentum |  |
| May. 16 | Bristol Myers Gets FDA OK of Breyanzi in Follicular Lymphoma | DJ |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 46.03B | Sales 2025 * | 46.12B | Capitalization | 90.31B |
|---|---|---|---|---|---|
| Net income 2024 * | -5.41B | Net income 2025 * | 10.22B | EV / Sales 2024 * | 2.81 x |
| Net Debt 2024 * | 39.2B | Net Debt 2025 * | 31.85B | EV / Sales 2025 * | 2.65 x |
| P/E ratio 2024 * |
-16.8
x | P/E ratio 2025 * |
8.33
x | Employees | 34,100 |
| Yield 2024 * |
5.45% | Yield 2025 * |
5.73% | Free-Float | 69.27% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bristol-Myers Squibb Company
More recommendations
More press releases
More news
| 1 day | -0.99% | ||
| 1 week | +1.01% | ||
| Current month | +0.39% | ||
| 1 month | -9.07% | ||
| 3 months | -10.78% | ||
| 6 months | -14.47% | ||
| Current year | -14.03% |
1 week
43.68
45.72
1 month
43.3349.56
Current year
43.3355.04
1 year
43.3367.35
3 years
43.3381.44
5 years
42.4881.44
10 years
42.4881.44
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 15-01-31 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 19-11-19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 19-11-19 |
Peter Arduini
BRD | Director/Board Member | 59 | 16-03-31 |
Derica Rice
BRD | Director/Board Member | 59 | 20-08-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 12.97% | 254 M€ | +10.74% | - | |
| 4.99% | 2 M€ | -.--% | ||
| 4.01% | 17 M€ | +7.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 44.11 | -0.99% | 15,765,711 |
| 24-05-15 | 44.55 | -0.36% | 14,179,383 |
| 24-05-14 | 44.71 | -0.78% | 14,536,549 |
| 24-05-13 | 45.06 | +0.27% | 12,642,469 |
| 24-05-10 | 44.94 | +0.45% | 8,699,595 |
Delayed Quote Nyse, May 16, 2024 at 04:00 pm EDT
More quotes
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Calendar
2024-07-26
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
44.55
USD
Average target price
53.19
USD
Spread / Average Target
+19.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.03% | 90.31B | |
| +32.36% | 709B | |
| +30.77% | 595B | |
| -1.60% | 367B | |
| +20.07% | 334B | |
| +6.04% | 289B | |
| +14.77% | 239B | |
| +9.13% | 211B | |
| -3.97% | 203B | |
| +9.27% | 171B |
- Stock Market
- Equities
- BMY Stock
